GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (XPAR:ALMDP) » Definitions » Insider Ownership

Medesis Pharma (XPAR:ALMDP) Insider Ownership : 0.00 % (As of May. 13, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Medesis Pharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medesis Pharma's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medesis Pharma's Institutional Ownership is 0.76%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medesis Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Medesis Pharma Insider Ownership Historical Data

The historical data trend for Medesis Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma Insider Ownership Chart

Medesis Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
Get a 7-Day Free Trial - - - - -

Medesis Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Medesis Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Medesis Pharma Business Description

Traded in Other Exchanges
Address
Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670
Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines